FGEN FIBROGEN INC

Nasdaq fibrogen.com


$ 10.96 $ 0.42 (3.98 %)    

Monday, 13-Oct-2025 15:59:53 EDT
QQQ $ 595.94 $ 0.00 (0 %)
DIA $ 458.58 $ 0.00 (0 %)
SPY $ 658.04 $ 0.00 (0 %)
TLT $ 91.16 $ 0.00 (0 %)
GLD $ 380.67 $ 0.00 (0 %)
$ 10.97
$ 10.78
$ 10.97 x 4
$ 12.35 x 150
-- - --
$ 4.50 - $ 21.94
16,211
na
44.36M
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-fibrogen-maintains-43-price-target

HC Wainwright & Co. analyst Matthew Keller reiterates FibroGen (NASDAQ:FGEN) with a Buy and maintains $43 price target.

 fibrogen-begins-phase-2-trial-of-new-prostate-cancer-drug-fg-3246-with-ucsf-as-first-site

FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a p...

 fibrogen-confirms-regulatory-approval-for-sale-of-fibrogen-international-hong-kong-ltd-to-astrazeneca-treasury-limited

Sale of FibroGen China remains on track to close in 3Q 2025

Core News & Articles

Recent Developments and Key Highlights of Second Quarter 2025: Sale of FibroGen China to AstraZeneca now expected to be for a t...

 fibrogen-q2-eps-188-beats-225-estimate-sales-135m-miss-263m-estimate

FibroGen (NASDAQ:FGEN) reported quarterly losses of $(1.88) per share which beat the analyst consensus estimate of $(2.25) by 1...

 hc-wainwright--co-maintains-buy-on-fibrogen-raises-price-target-to-43

HC Wainwright & Co. analyst Matthew Keller maintains FibroGen (NASDAQ:FGEN) with a Buy and raises the price target from ...

 fibrogen-announces-positive-feedback-from-type-c-meeting-with-fda-supporting-advancement-of-roxadustat-for-treatment-of-anemia-in-patients-with-lr-mds-and-high-rbc-transfusion-burden

FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat fo...

 fibrogen-terminates-license-agreement-with-hifibio-transfers-anti-ccr8-and-anti-gal-9-assets-and-secures-potential-royalties-from-future-sublicensing-or-commercialization

On June 12, 2025, FibroGen ("FibroGen" or the "Company") entered into a Termination, Asset Transfer and License...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION